Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — ØU Life Science Investor Conference (September 2021)
22 slides from Expres2ion Biotech Holding Ab's conference presentation, Sep 22, 2021
Slide 1: Proteins for Life
22nd September, 2021 Proteins for Life ØU Life Science Investor Conference Copenhagen, Denmark Bent U. Frandsen, CEO
Slide 2: Forward-looking statements and disclaimer
Forward-looking statements and disclaimer This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this pre
Slide 3: Investment Highlights
Investment Highlights Key player in advanced protein sciences with novel pipeline addressing 45B EUR markets Leader in production of complex proteins with the advantageous ExpreS2 technology Co-Founder of AdaptVac ApS, owner of a unique Virus Like Particle (VLP) technology Pipeline of therapeutics/v
Slide 4: Deep Pipeline for Value Creation
Deep Pipeline for Value Creation Development Progress DISEASE Project/Target Discovery Pre-clinical cGMP / Tox Phase 1 Phase 2 Phase 3 Market Partner/Funding Pharmacology Potential > 30 Coronavirus ABNCoV2/SARS-CoV-2 cVLP I / II BN: II billion EUR PREVENT-nCoV > 10 100% Breast Cancer ES2B-C001/HER2
Slide 5: Management Team
Management Team Expanded team in 2021 brings skills to build our pipeline-focused business Started Bent U. Frandsen, CEO Dr. Mette Thorn, VP Preclinical Development in 2021 • MSc. In Finance/Strategic Management, Copenhagen Business School, • PhD in Immunology, and a MSc in Chem Eng., Tech. Univ of
Slide 6: Board of Directors
Board of Directors Expanded the Board in 2021 in support of the transition to a pipeline-focused business Re- Elected Dr. Martin Roland Jensen, Chairman elected Dr. Karin Garre, Board Member in 2021 • PhD. in Molecular and Cell Biology, Univ. of Copenhagen, Denmark • MD, from University of Copenhage
Slide 7: Our Programs
Our Programs Proteins for Life
Slide 8: Breast Cancer
BREAST CANCER The Most Common Cancer 1 in 8 women will be diagnosed with invasive breast cancer in her lifetime ~25% have overexpression of HER2 receptors, associated with more aggressive tumors and reduced survival2 685,000 deaths worldwide in 2020 due to breast cancer1 Proteins 1. Breast Cancer fo
Slide 9: HER2+ Breast Cancer Overview
BREAST CANCER HER2+ Breast Cancer Overview The ES2B-C001 vaccine can offer significant benefits compared to current treatment options Over 180,000 people diagnosed with HER2+ breast Monoclonal antibodies are the cornerstone of treatment cancer per year across US, EU, & Japan1,2 for HER2+ breast canc
Slide 10: ES2B-C001 overcomes Herceptin resistance
BREAST CANCER ES2B-C001 overcomes Herceptin resistance The soft agar human cancer cell growth inhibition assay provides in vitro evidence UNTREATED ES2B-C001 Trastuzumab- sensitive HER2+ human Both Herceptin (trastuzumab) and cancer cells1 ES2B-C001 inhibited growth in the trastuzumab-sensitive cell
Slide 11: Strong Preclinical Data for VLP Approach
BREAST CANCER Strong Preclinical Data for VLP Approach ES2B-C001 has demonstrated animal proof-of-concept, and on track to repeat in vivo PoC • Prevention of 50-100% of spontaneous mammary carcinogenesis Preventive studies (mice with pre-disposition to • Strong tumor growth inhibition in spontaneous
Slide 12: Influenza & Malaria
INFLUENZA & MALARIA Influenza & Malaria Influenza Vaccine Malaria Vaccine >4 billion EUR >0.4 billion EUR The INDIGO consortium 5 vaccines candidates under development that target • Led by University of Amsterdam various stages of disease & transmission • Multiple research groups, incl. ExpreS2ion I
Slide 13: The 2nd Generation COVID-19 Vaccine
CORONAVIRUS nd The 2 Generation COVID-19 Vaccine With over 4.6 million deaths worldwide, significant needs remain in the global long-term fight against the SARS-CoV-2 virus: Uncertain duration of effect with current vaccines, expected to need repeated boosters Storage and handling requirements for m
Slide 14: The Best COVID-19 Vaccine
CORONAVIRUS The Best COVID-19 Vaccine PREVENT-nCoV ABNCoV2 has demonstrated superior preclinical proof-of-concept, and now promising human data Encouraging early findings: Phase I/II Study headline results: Virus • Durable immune response with • 45 humans dosed (6-70µg) Spike proteins on single shot
Slide 15: ABNCoV2: Positive Phase I/II Outcomes
CORONAVIRUS ABNCoV2: Positive Phase I/II Outcomes Exceptional safety & tolerability, as well as high neutralizing effect against variants ABNCoV2 induces high neutralization titers vs ABNCoV2 also induces higher neutralization against recovered COVID-19 patients (HCS) variants vs recovered COVID-19
Slide 16: COVID-19 License and JV Economics
CORONAVIRUS COVID-19 License and JV Economics ABNCoV2 is already out-licensed with near-term revenue streams supporting ExpreS2ion AdaptVac’s Economics ExpreS2ion’s Economics Paid by Bavarian Nordic Paid by AdaptVac • 4 MEUR upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to 136 MEUR in
Slide 17: COVID-19 Value to ExpreS2ion
CORONAVIRUS 2 COVID-19 Value to ExpreS ion Institutional analysts have higher sales and approval assumptions Estimated COVID-19 + AdaptVac value1 2,800 Danske Bank Carnegie 2,500 Pareto: SEK 68 target COVID-19 + AdaptVac value: SEK 1,322 mn (60.9% of company valuation) Institutional 2,200 SEK millio
Slide 18: Financials & Corporate Outlook
Financials & Corporate Outlook Proteins for Life
Slide 19: Exercise of Warrant Programme TO5
Exercise of Warrant Programme TO5 Window open during September 6-20 – Strike price determined to be 25 SEK / share • 5.5 million TO5 warrants, part of the October 2020 successfully oversubscribed rights issue • Exercise window September 6-20, 2021 • Strike price equal to 70% of VWAP during 10 tradin
Slide 20: 2Q21 - Key Financial Developments
2Q21 - Key Financial Developments Operating income, SEK ‘000s Operating profit (loss), SEK ‘000s Cash, SEK millions – excluding TO5 proceeds 6.000 0 120 5.000 -3.000 100 4.000 -6.000 80 3.000 -9.000 60 2.000 -12.000 40 1.000 -15.000 20 0 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 Non-Grant Gr
Slide 21: 2021 – 2023 Outlook
2021 – 2023 Outlook On track to deliver shareholder value 2021 2022 2023 CORONAVIRUS (ABNCoV2) Phase I/II COUGH-1 COUGH-1 BN Phase II BN Phase II BN Phase III BN Phase III BN ready for trial, initial full safety trial trial trial initial market launch COUGH-1 safety & efficacy initiation readout ini
Slide 22: Thank you!
Thank you! Contact: info@expreS2ionbio.com Proteins for Life 22
ExpreS2ion Biotech — ØU Life Science Investor Conference (September 2021) on 6ix